
PNKP
26
MENTIONS
2
EPISODES
1
PODCASTS
Search complete. 26 mentions across 2 episodes found for "PNKP".
Sep 10, 2026
The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF)
I
7:32Islam MohamedGUEST
It's headquartered in Calgary, and we're developing a first-in-class DNA damage response inhibitor against a novel target.
I
7:39Islam MohamedGUEST
So that's a DNA repair enzyme called polynucleotide kinase phosphatase, or PNKP.
I
7:46Islam MohamedGUEST
As far as we're aware, there is no clinical stage PNKP program anywhere in the world.
I
7:51Islam MohamedGUEST
We hold exclusive worldwide rights to the University of Alberta's foundational PNKP inhibitor patents, together with an exclusive sub-license to the nanoparticle delivery platform that accompanies it.
I
8:05Islam MohamedGUEST
Our lead candidate in this space is Onco10.
I
8:10Islam MohamedGUEST
That's a combination of the PNKP inhibitor called A83B4C63.
I
8:16Islam MohamedGUEST
And that's encapsulated within a nanoparticle to improve how long it circulates and how it accumulates in the tumor.
I
8:23Islam MohamedGUEST
So in laboratory and animal studies, it demonstrates two distinct behaviors.
The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) [Video Edition]
I
7:32Islam MohamedGUEST
It's headquartered in Calgary, and we're developing a first-in-class DNA damage response inhibitor against a novel target.
I
7:39Islam MohamedGUEST
So that's a DNA repair enzyme called polynucleotide kinase phosphatase, or PNKP.
I
7:46Islam MohamedGUEST
As far as we're aware, there is no clinical stage PNKP program anywhere in the world.
I
7:51Islam MohamedGUEST
And we hold exclusive worldwide rights to the University of Alberta's foundational PNKP inhibitor patents, together with an exclusive sub-license to the nanoparticle delivery platform that accompanies it.
I
8:05Islam MohamedGUEST
So our lead candidate in this space is Onco10.
I
8:10Islam MohamedGUEST
So that's a combination of the PNKP inhibitor called A83B4C63, and that's encapsulated within a nanoparticle to improve how long it circulates and how it accumulates in the tumor.
I
8:23Islam MohamedGUEST
In laboratory and animal studies, it demonstrates two distinct behaviors.
I
8:27Islam MohamedGUEST
In tumors that have lost a tumor suppressor gene, one called PTEN or P10, and another one called SHP1, It can kill cancer cells acting via synthetic lethality just with the drug alone.